Tharimmune, Inc. (THAR)
Tharimmune, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bridgewater, NJ, US. The stock last traded at $3.54, up 6.63% on the session, giving a market capitalisation of $139.9M. On trailing twelve-month figures it carries a trailing P/E of -1.77, a net margin of 0.0%. Its beta of 1.45 implies it has historically moved more than the broad market.
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.
Tharimmune, Inc. is most often compared with the following Healthcare names: